Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel – an update

Bruce D. ChesonLombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC, USA; Correspondence[email protected]

Wolfram BruggerSchwarzwald-Baar Clinic, University of Freiburg, Villingen-Schwenningen, Germany;

Gandhi DamajUniversity Hospital, University of Basse-Normandie, Caen, France;

Martin DreylingMedical Clinic, University Hospital of Munich, Munich, Germany;

Brad KahlUniversity of Wisconsin School of Medicine and Public Health, Madison, WI, USA;

Eva KimbyCenter for Hematology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden;

Michinori OguraDepartment of Hematology, Tokai Central Hospital, Gifu, Japan;

Eckhart WeidmannDepartment of Oncology and Hematology, Krankenhaus Nordwest, Frankfurt, Germany;

Clemens-Martin WendtnerKlinikum Schwabing, Academic Teaching Hospital of University of Munich, Munich, Germany;

Pier Luigi ZinzaniInstitute of Hematology, University of Bologna, Bologna, Italy

Your download is now in progress and you may close this window